



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 9/00	A2	(11) International Publication Number: WO 00/37613 (43) International Publication Date: 29 June 2000 (29.06.00)
(21) International Application Number: PCT/GB99/04311 (22) International Filing Date: 17 December 1999 (17.12.99) (30) Priority Data: 9828375.7 22 December 1998 (22.12.98) GB (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): MASURE, Stefan, Leo, Jozef [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). RICHARDSON, Alan [GB/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). (74) Agent: BOULT WADE TENNANT; Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: HUMAN AKT-3 (57) Abstract <p>There is disclosed a nucleic acid molecule encoding human Akt-3 protein or a functional equivalent or bioprecursor thereof comprising the amino acid sequence illustrated in Sequence ID No. 3. The human Akt-3 protein itself also forms part of the invention. The nucleic acid molecule and the human Akt-3 protein may themselves be used as medicaments, or in the preparation of medicaments for treating cancer, in their own right or in the form of a pharmaceutically acceptable carrier, diluent or excipient thereof. Further disclosed are methods of identifying agents which influence the activity of a human Akt-3 protein.</p> <div style="display: flex; justify-content: space-between;"><div style="width: 45%;"><p>1 GGGAGTCATCATGAGCGATGTTACCATTTGTGAAGAAGAGTTGGGTCAGAAGAGGGGAGA 61 ATATATAAAAACTGGAGGCCAAGATACTCTCTTTGAAGACAGATGGCTCATTATAGG 121 V K E K G K P O D V D L P Y F L L K T D G S F I I G 181 ATATAAAGAGAAACCTCAAGATGTGGATTACCTTATCCCTCAACACATTTTCAGTGGC 241 K C Q L H K K T E R K K P N T F I I R C L 301 AAAATGCCAGTTAATGAAGAACAGAACCAAGCCAAACACATTTATATCAGATGTCT 361 O W T T V I E R T F H V D T P E E R E E 421 CCAGTGGACTACTGTTATAGAGAGAACATTTCTATGTAGTACTCCAGAGGAAAGGGAAGA 481 W T E A I O A V A D R L O R O E E E E R M 541 ATGGACAGAAGCTATCCAGGCTGTAGCAGACAGACTGCCAGGCCAAGAGAGGAGAGAAAT 601 N C S P T S O I D N I G E E E E M D A S T 661 GAATGTAGTCCAACTTCACAAATGTATAATATAGGAGAGGAGAGATGGCTCTAC 721 T H H K R K K T H N D F D V L K L L G K K G 781 AACCCATCATAAAGAGAAAGCAATGAATGATTTTGACTATTGAACTACTAGGTAAAGG 841 T F G K V I L V R R E K A S O K Y V A H M K 901 CACTTTTGGGAAGTTATTTTGGTTCGAGAGAGGCAAGTGGGAAATATCTATGCTATGAA 961 I L K K K E V I I A K A D E V A N T L T E S 1021 GATTCTGAAGAAAGATCATTTATTCAGAGATGAAGTGGCACACACTCTAACTGAAAG 1081 R V L K K N T R R H P F L T T S L K K Y S F O T 1141 CAGAGTATTAAAGAACACTAGACATCCCTTTTAACTCTCTGAAATATCTCTCCAGAC 1201 K D R L C F V N E Y V N G G G E L F F H L 1261 AAAAGACCGTTTGTGTTTGTGATGGAATATGTTAAATGGGGCGAGCTGTTTTCATT 1321 S R E R V F S E D R T R F Y G A E I V S 1381 GTCGAGAGCGGGTGTCTCTGAGGACCGCACAGTTTCTATGTTGAGAGAAATGTCTC 1441 A L D Y L H S G K I V Y R D K L E N L 1501 TGCCTTGACTATCTAATTCGGGAAAGATTGTGTACCGTGATCTCAAGTTGGGAATCT 1561 H L D K D G H I K I T D F G L K K E G I 1621 AATGCTGGACAAAGATSGCCACATAAATAATCAGATTTTGGACTTTGCAAGAAAGGGAT 1681 T D A A T M K E F C G T P E Y L A P E V 1741 CACAGATGCAGCCACCATGAAGACATTTCTGTGGCCTCAGAAATATCTGGCACCAGAGGT 1801 L E D N D Y G R A V D W W G L G V V N Y 1861 GTTAGAAGATAATGACTATGGCCGAGCAGTAGACTGGTGGGGCTAGGGGTGTCTCATGTA 1921 E H M C G R L P F Y N O D H E K L F E L 1981 TGAAATGATGTGGAGGT-TACCTTTCTACAACAGGACCATGAGAACTTTTGAAT 2041 I L H E D I K F P R T L S S D A K S L L 2101 AATATTAAATGGAAGACATTAAATTTCTCGAACACTCTTCAGATGCAAAATCTGCT 2161 S G L L I K D P N K R L G G G P D D A K 2221 TTCAGGGCTCTTGATAAGGATCCAAATAAACCCCTTGGTGGAGGACCATGATGCAAA 2281 E I M R H S F F S G V N W O D V Y D K K 2341 AGAAATATGAGACACAGTTCTCTCTGGAGTAAATGGCAGATGTATATGATAAA 2401 L V P P P F K P O V T A E T S E T D T R Y F D G 2461 GCTGTACTCTCTTTAAACCTCAAGTAACTATCAGACAGATACTAGATATTTGATGA 2521 E F T A O T I T T P P E K Y D E D G 2581 AGAATTTACAGCTCAGACTATTACAAATAACACCCTGAAAAATATGATGAGCATGTAT 2641 G G A T T G C A T G G A C A T A G A G G C C C A T T T C C A T T T C T A C T G C A T G G 2701 A C C A A T A A G T C T T T C A T T C T G C T A C T G C A C T G C A T T T A T T A C T A G A A A 2761 T G A T T C C T G G A C A T C A C C A G T C T A G C T T T A C A C A T A G C A G G G G A</p></div><div style="width: 45%; text-align: right;"><p>17 37 57 77 97 117 137 157 177 197 217 237 257 277 297 317 337 357 377 397 417 437 457 477 497</p></div></div>		